The purpose of this notice of funding opportunity (NOFO) is to support research to elucidate how HIV-induced immunometabolic alterations, in a host suppressed on combination antiretroviral therapy (cART-suppressed), impact the immune response and increase risk for poor outcomes due to a second, potentially
long-term, infection such as Mycobacterium tuberculosis (Mtb) or hepatitis B virus (HBV).
This NOFO aims to support research to define how HIV-driven alterations to immunometabolism affect immune cell regulation, cell-cell interactions, response to treatment, and, ultimately, tuberculosis (TB) and HBV disease progression.